Mesoblast Limited
MESO
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platformā¦ read more
Healthcare
Biotechnology
16 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$14.17
Price-2.61%
-$0.38
1Y
Price
Market Cap
$1.838b
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-48.8%
EBITDA Margin-78.2%
Net Profit Margin-17.4%
Free Cash Flow Margin-48.8%
EBITDA Margin-78.2%
Net Profit Margin-17.4%
Free Cash Flow MarginRevenue
$65.384m
+280.2%
1y CAGR+150.1%
3y CAGR+105.9%
5y CAGREarnings
-$94.370m
+7.6%
1y CAGR-5.3%
3y CAGR-1.4%
5y CAGREPS
-$0.72
+14.3%
1y CAGR+9.7%
3y CAGR+13.4%
5y CAGRBook Value
$574.684m
$782.307m
Assets$207.623m
Liabilities$135.144m
DebtDebt to Assets
17.3%
-2.1x
Debt to EBITDAFree Cash Flow
-$50.345m
+0.7%
1y CAGR+6.7%
3y CAGR+5.9%
5y CAGRNo items found.
Press Releases
Statements and updates from the company